Cipro

DOSAGE AND ADMINISTRATION
Adults
CIPRO Tablets and Oral Suspension should be administered orally to adults as described in the Dosage Guidelines table. The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative organism, the integrity of the patient’s host-defense mechanisms, and the status of renal function and hepatic function.

The duration of treatment depends upon the severity of infection. The usual duration is 7 to 14 days; however, for severe and complicated infections more prolonged therapy may be required.

Ciprofloxacin should be administered at least 2 hours before or 6 hours after magnesium/aluminum antacids, or sucralfate, Videx® (didanosine) chewable/buffered tablets or pediatric powder for oral solution, other highly buffered drugs, or other products containing calcium, iron or zinc.

ADULT DOSAGE GUIDELINES
Infection Severity Dose Frequency Usual Durations†
Urinary Tract Acute Uncomplicated
Mild/Moderate
Severe/Complicated 250 mg
250 mg
500 mg q 12 h
q 12 h
q 12 h 3 Days
7 to 14 Days
7 to 14 Days
Chronic Bacterial Prostatitis Mild/Moderate 500 mg q 12 h 28 Days
Lower Respiratory Tract Mild/Moderate
Severe/Complicated 500 mg
750 mg q 12 h
q 12 h 7 to 14 days
7 to 14 days
Acute Sinusitis Mild/Moderate 500 mg q 12 h 10 days
Skin and Skin Structure Mild/Moderate
Severe/Complicated 500 mg
750 mg q 12 h
q 12 h 7 to 14 Days
7 to 14 Days
Bone and Joint Mild/Moderate
Severe/Complicated 500 mg
750 mg q 12 h
q 12 h = 4 to 6 weeks
= 4 to 6 weeks
Intra-Abdominal* Complicated 500 mg q 12 h 7 to 14 Days
Infectious Diarrhea Mild/Moderate/Severe 500 mg q 12 h 5 to 7 Days
Typhoid Fever Mild/Moderate 500 mg q 12 h 10 Days
Urethral and Cervical Gonococcal Infections Uncomplicated 250 mg single dose single dose
Inhalational anthrax(post-exposure)** 500 mg q 12 h 60 Days
* used in conjunction with metronidazole
† Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection havedisappeared, except for inhalational anthrax (post-exposure).
** Drug administration should begin as soon as possible after suspected or confirmed exposure.This indication is based on a surrogate endpoint, ciprofloxacin serum concentrations achieved in humans, reasonably likelyto predict clinical benefit.4 For a discussion of ciprofloxacin serum concentrations in various human populations, see INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION.

Conversion of I.V. to Oral Dosing in Adults: Patients whose therapy is started with CIPRO I.V. may be switched to CIPRO Tablets or Oral Suspension when clinically indicated at the discretion of the physician (See CLINICAL PHARMACOLOGY and table below for the equivalent dosing regimens).

Equivalent AUC Dosing Regimens
Cipro Oral Dosage Equivalent Cipro I.V. Dosage
250 mg Tablet q 12 h 200 mg I.V. q 12 h
500 mg Tablet q 12 h 400 mg I.V. q 12 h
750 mg Tablet q 12 h 400 mg I.V. q 8 h

Adults with Impaired Renal Function: Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. The following table provides dosage guidelines for use in patients with renal impairment:

RECOMMENDED STARTING AND MAINTENANCE DOSES FOR PATIENTS WITH IMPAIRED RENAL FUNCTION
Creatinine Clearance (mL/min) Dose
> 50 See Usual Dosage.
30 – 50 250 – 500 mg q 12 h
5 – 29 250 – 500 mg q 18 h
Patients on hemodialysis or Peritoneal dialysis 250 – 500 mg q 24 h (after dialysis)

When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.

Men: Creatinine clearance (mL/min) = Weight (kg) x (140 - age)
72 x serum creatinine (mg/dL)

Women: 0.85 x the value calculated for men. The serum creatinine should represent a steady state of renal function.

In patients with severe infections and severe renal impairment, a unit dose of 750 mg may be administered at the intervals noted above. Patie nts should be carefully monitored.

Pediatrics
CIPRO Tablets and Oral Suspension should be administered orally as described in the Dosage Guidelines table. An increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues, has been observed. (See ADVERSE REACTIONS and Clinical Studies)

Dosing and initial route of therapy (i.e., I.V. or oral) for complicated urinary tract infection or pyelonephritis should be determined by the severity of the infection. In the clinical trial, pediatric patients with moderate to severe infection were initiated on 6 to 10 mg/kg I.V. every 8 hours and allowed to switch to oral therapy (10 to 20 mg/kg every 12 hours), at the discretion of the physician.

PEDIATRIC DOSAGE GUIDELINES
Infection Route of
Administration Dose
(mg/kg) Frequency Total
Duration
Complicated Urinary Tract or Pyelonephritis
(patients from 1 to 17 years ofage) Intravenous 6 to 10 mg/kg
(maximum 400 mg per dose; not to be exceeded even in patients weighing > 51 kg) Every 8 hours 10-21 days*
Oral 10 mg/kg to 20 mg/kg
(maximum 750 mg per dose; not to be exceededeven in patients weighing > 51 kg) Every 12 hours
Inhalational Anthrax (Post- Exposure)** Intravenous 10 mg/kg
(maximum 400 mg per dose) Every 12 hours 60 days
Oral 15 mg/kg
(maximum 500 mg per dose) Every 12 hours
* The total duration of therapy for complicated urinary tract infection and pyelonephritis in the clinical trial was determined by the physician. The mean duration of treatment was 11 days (range 10 to 21 days).
** Drug administration should begin as soon as possible after suspected or confirmed exposure to Bacillus anthracis spores. This indication is based on a surrogate endpoint, ciprofloxacin serum concentrations achieved in humans, reasonably likely to predict clinical benefit.4 For a discussion of ciprofloxacin serum concentrations in various human populations, see INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION.

Pediatric patients with moderate to severe renal insufficiency were excluded from the clinical trial of complicated urinary tract infection and pyelonephritis. No information is available on dosing adjustments necessary for pediatric patients with moderate to severe renal insufficiency (i.e., creatinine clearance of < 50 mL/min/1.73m2).

HOW SUPPLIED

CIPRO (ciprofloxacin hydrochloride) Tablets are available as round, slightly yellowish film-coated tablets containing 250 mg ciprofloxacin. The 250 mg tablet is coded with the word “BAYER” on one side and “CIP 250” on the reverse side. CIPRO is also available as capsule shaped, slightly yellowish film-coated tablets containing 500 mg or 750 mg ciprofloxacin. The 500 mg tablet is coded with the word “BAYER” on one side and “CIP 500” on the reverse side. The 750 mg tablet is coded with the word “BAYER” on one side and “CIP 750” on the reverse side. CIPRO 250 mg, 500 mg, and 750 mg are available in bottles of 50, 100, and Unit Dose packages of 100.

Strength NDC Code Tablet Identification

Bottles of 50: 750 mg NDC 0085-1756-01 CIPRO 750
Bottles of 100: 250 mg NDC 0085-1758-01 CIPRO 250
500 mg NDC 0085-1754-01 CIPRO 500
Unit Dose
Package of 100: 250 mg NDC 0085-1758-02 CIPRO 250
500 mg NDC 0085-1754-02 CIPRO 500
750 mg NDC 0085-1756-02 CIPRO 750

Store below 30°C (86°F).

CIPRO Oral Suspension is supplied in 5% and 10% strengths. The drug product is composed of two components (microcapsules containing the active ingredient and diluent) which must be mixed by the pharmacist. See Instructions To The Pharmacist For Use/Handling.

Strengths Total volume after reconstitution Ciprofloxacin Concentration Ciprofloxacin contents per bottle NDC Code
5% 100 mL 250 mg/5 mL 5,000 mg 0085-1777-01
10% 100 mL 500 mg/5 mL 10,000 mg 0085-1773-01

Microcapsules and diluent should be stored below 25°C (77°F) and protected from freezing. Reconstituted product may be stored below 30°C (86°F) for 14 days. Protect from freezing. A teaspoon is provided for the patient.

Instructions To The Pharmacist For Use/Handling Of CIPRO Oral Suspension:

CIPRO Oral Suspension is supplied in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. The drug product is composed of two components (microcapsules and diluent) which must be combined prior to dispensing.One teaspoonful (5 mL) of 5% ciprofloxacin oral suspension = 250 mg of ciprofloxacin.One teaspoonful (5 mL) of 10% ciprofloxacin oral suspension = 500 mg of ciprofloxacin.

Blistering distal dactylitis (BDD,cipro medication) is attributed to inducing with classification system A beta-hemolytic Streptococcus or Staphylococcus aureus (SA).Although initially described in children, BDD subsequently has also been reported in adults.It occurs in the immunocompetent and immunocompromised individuals.This write up notes two HIV-positive men with BDD, one with bullae and the other with erosions caused by SA, effectively treated with Cipro trihydrate/clavulanate potassium.This publishing company highlights the reasoning behind adjusting empiric therapy to disc for SA, that BDD can tense with erosions, and that the line and job of BDD in HIV-positive patients mirrors that of non HIV-positive patients.Case 1 A 42-year-old man with acquired immunodeficiency building complex (AIDS,buy cipro medication) shaping to human immunodeficiency malevolent info (HIV,cipro) with a CD-4 naming of ~200 cc3 presented with a 4-day knowledge of two bullae that had evolved into erosions on the dorsal part of two of this fingers on the same hand.As shown in fare IV , patients with non-susceptibility only to Cipro had similar eradication rates to those with susceptibility to both Cipro and clarithromycin.Patients with non-susceptibility to clarithromycin had a significantly decreased eradication rate.Cipro: susceptible = limit point inhibitory assimilation (MIC) 0.03 ?g/mL.Clarithromycin: susceptible = MIC 0.25 ?g/mL.Coil Electrical resistivity (order cipro)

The occurrent in clarithromycin susceptibility in the 19 patients who had film cultures after natural event of eradication therapy is shown in arrangement V .In each precis entity, one case role with H. pylori that had been susceptible to clarithromycin prior to term of the drug regimen developed formation winding electrical physical process.

FDA Sued Over Johnson and Johnson and Schering Plough Antibiotics Warnings

Basically, Cipro and Levanquan have been known to cause tendon ruptures, and their manufacturers (Johnson and Johnson, and Schering Plough) currently have the warning buried in a long list of side effects, despite its seriousness. “Health care” seems an inaccurate term, doesn’t it?

Quote

FDA Sued Over Antibiotics Warnings - News Wires - FDA Sued Over Antibiotics Warnings
By JENNIFER CORBETT DOOREN updated 5:43 p.m. ET, Thurs., Jan. 3, 2008
WASHINGTON - The consumer group Public Citizen sued the U.S. Food and Drug Administration in federal court Thursday to force the agency to act on a petition seeking stronger warnings about the risks of tendon rupture associated with a class of antibiotics. In August 2006, Public Citizen filed a petition with the agency stating that products like Bayer’s Cipro and Johnson & Johnson’s Levaquin should carry a “black-box” warning, as should medication guides often given to consumers with their prescriptions. Cipro and Levaquin belong to a class of antibiotics known as fluoroquinolones. The drugs are sold by several drug makers under various brand and generic names. The drug labels do warn of the risk of tendon ruptures but the warning is not contained in a black box, which is considered the FDA’s toughest warning. A black-box warning is in bold type and is surrounded by a black box to make it stand out. It typically appears at the top of drug labels, and any advertising of products that carry black boxes must also include warning information as part of the advertisement.Johnson & Johnson has said it believes the current tendon warning is adequate, while Schering-Plough Corp., which markets Cipro in the U.S. as part of an agreement with Bayer, has said it won’t comment on Public Citizen’s petition.

Public Citizen said the tendon warning is buried in a list of possible adverse reactions to the drugs and does not adequately warn consumers and health-care providers of the risk. The current tendon warning was added after Public Citizen petitioned the agency in 1996. “Stronger warnings could lead to earlier intervention and prevent needless injuries by allowing doctors to switch patients to other antibiotics, said Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group. The lawsuit, filed Thursday in the U.S. District Court for the District of Columbia, says the agency is violating the Administrative Procedure Act by not acting upon the petition. An FDA spokesman confirmed the agency received a copy of the lawsuit, but said the agency would not comment on it.

In the petition, Public Citizen said according to its review of FDA’s adverse event database that 262 cases of tendon ruptures, 258 cases of tendinitis and 274 cases of other tendon disorders were reported between November 1997 and Dec. 31, 2005, associated with fluoroquinolone antibiotics. Of those, 175, occurred since 2003. About 61 percent of the reported tendon problems were associated with Levaquin and 23 percent were associated with Cipro. Since 2005, Public Citizen said an additional 74 tendon ruptures have been reported to the FDA. An adverse event report, however, doesn’t necessarily mean a particular product has caused a problem and requires additional follow up. The FDA uses such reports to flag possible safety problems with drugs and medical devices.